Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hospital Acquired Infections Therapeutics Market

Hospital Acquired Infections Therapeutics Market Share

Report ID: GMI11913
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Hospital Acquired Infections Therapeutics Market Share

Several leading companies, such as Pfizer, Merck & Co., and GlaxoSmithKline, are actively involved in the development of new antimicrobial agents and therapies for HAIs. Recent industry developments include the approval of novel antibiotics and the expansion of research programs focused on multi-drug-resistant pathogens.

Hospital Acquired Infections Therapeutics Market Companies

Prominent players operating in the hospital acquired infections therapeutics industry include:

Abbott
AbbVie
Allergan Plc
Eugia Pharma
Bayer
DAIICHI SANKYO COMPANY
F. Hoffmann-La Roche
Glenmark Pharmaceuticals
GSK
Hikma Pharmaceuticals
Melinta Therapeutics
Merck & Co.
Pfizer
Sanofi
Viatris

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for hospital-acquired infections therapeutics was valued at approximately USD 12.6 billion in 2023 and is expected to reach around USD 16.4 billion by 2032, driven by a CAGR of 3.2% from 2024 to 2032.

Antibacterial drugs accounted for the highest revenue of USD 9.2 billion in 2023, driven by the increasing prevalence of antibiotic-resistant bacteria in healthcare settings.

North America market generated USD 4.7 billion in 2023, driven by its high incidence of HAIs and a well-established healthcare infrastructure.

Major players in the industry include Abbott, AbbVie, Allergan Plc, Eugia Pharma, Bayer, DAIICHI SANKYO COMPANY, F. Hoffmann-La Roche, Glenmark Pharmaceuticals, GSK, and Hikma Pharmaceuticals.